Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) - Equities researchers at B. Riley issued their Q1 2025 earnings per share estimates for Eton Pharmaceuticals in a report issued on Thursday, January 9th. B. Riley analyst M. El-Saadi anticipates that the company will post earnings of $0.03 per share for the quarter. B. Riley currently has a "Strong-Buy" rating on the stock. The consensus estimate for Eton Pharmaceuticals' current full-year earnings is ($0.17) per share. B. Riley also issued estimates for Eton Pharmaceuticals' Q4 2025 earnings at $0.12 EPS.
Several other analysts also recently weighed in on ETON. HC Wainwright lifted their target price on shares of Eton Pharmaceuticals from $15.00 to $17.00 and gave the company a "buy" rating in a report on Monday, January 6th. Craig Hallum boosted their target price on Eton Pharmaceuticals from $15.00 to $18.00 and gave the stock a "buy" rating in a research report on Wednesday, January 8th.
View Our Latest Stock Report on ETON
Eton Pharmaceuticals Price Performance
NASDAQ:ETON opened at $13.44 on Monday. The firm has a market cap of $350.13 million, a price-to-earnings ratio of -61.09 and a beta of 1.38. Eton Pharmaceuticals has a 1-year low of $3.03 and a 1-year high of $15.00. The firm's fifty day moving average price is $11.74 and its 200 day moving average price is $7.48.
Hedge Funds Weigh In On Eton Pharmaceuticals
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Nantahala Capital Management LLC acquired a new stake in shares of Eton Pharmaceuticals in the second quarter valued at about $3,095,000. Wasatch Advisors LP purchased a new position in Eton Pharmaceuticals in the third quarter valued at about $1,431,000. Aristides Capital LLC acquired a new stake in shares of Eton Pharmaceuticals during the 2nd quarter valued at approximately $658,000. Thompson Siegel & Walmsley LLC acquired a new stake in shares of Eton Pharmaceuticals during the 2nd quarter valued at approximately $420,000. Finally, Stonepine Capital Management LLC purchased a new stake in shares of Eton Pharmaceuticals during the 2nd quarter worth approximately $362,000. 27.86% of the stock is owned by institutional investors and hedge funds.
Eton Pharmaceuticals Company Profile
(
Get Free Report)
Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.
Featured Articles
Before you consider Eton Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eton Pharmaceuticals wasn't on the list.
While Eton Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
